作者
Kaisa Maki-Petaja, Adam McGeoch, Lucy Yang, Annette Hubsch, Carmel McEniery, Fraz Mir, Parag Gajendragadkar, Nicola Ramenatte, Gayathri Anandappa, Christoph Brune, Yoeri Boink, Carola Bibiane-Schönlieb, Paul Meyer, Simon Bond, Ian Wilkinson, Duncan Jodrell, Joseph Cheriyan
发表日期
2018/12/1
简介
Introduction
Drugs targeting Vascular Endothelial Growth Factor (VEGF) signaling pathway are approved therapies for cancer. Unfortunately, VEGF inhibitors lead to hypertension in 30–80% patients. Reduced nitric oxide synthase activity and increased vascular resistance have been proposed as potential mechanisms. We aimed to assess these mechanisms in oncology patients receiving VEGF inhibitor, pazopanib (NCT01392352).
Methods
27 normotensive patients received pazopanib 800mg od. Endothelial function was assessed using forearm plethysmography with intra-arterial infusion of Acetylcholine (ACh), Sodium Nitroprusside (SNP) and L-N-mono-methyl-arginine (L-NMMA). Also, Blood Pressure (BP), Pulse Wave Velocity (PWV), Cardiac Output (CO), and Peripheral Vascular Resistance (PVR) and capillary density in the eye were assessed. All measurements were taken at baseline, 2 and 12 weeks after …
学术搜索中的文章
K Maki-Petaja, A McGeoch, L Yang, A Hubsch… - Artery Research, 2018